검색어 : 통합검색[Butler Ewan.]
총 35건 중 35건 출력
, 2/4 페이지
-
11
- BIOM-10. CLINICAL PERFORMANCE EVALUATION OF A BRAIN CANCER LIQUID BIOPSY
- Cameron, James; Baker, Matthew; Antoniou, Georgios; Brennan, Paul; Butler, Holly; Eustace, David; Gray, Ewan; Jakola, Asgeir; Jenkinson, Michael; Koljenovic, Senada; Lazarus, Alan; Mathew, Ryan; Palmer, David; Phang, Isaac; Sala, Alexandra; Weiss, Tobias; Dxcover Limited , Glasgow, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; University of Edinburgh , Edinburgh, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; Independant Health Economics Consultant , Edinburgh, United Kingdom; University of Gothenburg - The Sahlgrenska Academy , Gothenburg,; The Walton Centre , Liverpool, United Kingdom; University Hospital Antwerp , Antwerp,; Dxcover Limited , Glasgow, United Kingdom; Leeds Teaching Hospitals , Leeds, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; Royal Preston Hospital , Preston, United Kingdom; Dxcover Limited , Glasgow, United Kingdom; Universitä tsspital Zü rich , Zurich,; (Neuro-oncology, v.26, 2024, pp.viii20-viii21)
-
12
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
- Hamid, Omid; Robert, Caroline; Ribas, Antoni; Hodi, F. Stephen; Walpole, Euan; Daud, Adil; Arance, Ana S.; Brown, Ewan; Hoeller, Christoph; Mortier, Laurent; Schachter, Jacob; Long, Jianmin; Ebbinghaus, Scot; Ibrahim, Nageatte; Butler, Marcus; The Angeles Clinic and Research Institute, Los Angeles, CA USA; Gustave Roussy and Paris-Sud University, Villejuif, France; University of California, Los Angeles, Los Angeles, CA USA; Dana-Farber Cancer Institute, Boston, MA USA; Princess Alexandra Hospital, Brisbane, Australia; University of California, San Francisco, San Francisco, CA USA; Hospital Clinic de Barcelona, Barcelona, Spain; Edinburgh Cancer Research Centre and Western General Hospital, Edinburgh, Scotland UK; Medical University of Vienna, Vienna, Austria; Centre Hospitalier Ré gional Universitaire de Lille, Université Lille, Lille, France; Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel; Merck & Co., Inc, Kenilworth, NJ USA; Merck & Co., Inc, Kenilworth, NJ USA; Merck & Co., Inc, Kenilworth, NJ USA; Princess Margaret Cancer Centre, Toronto, ON Canada; (The British journal of cancer, v.119, 2018, pp.670-674)
-
13
- Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for <i>BRAF, PIK3CA, KRAS</i> , and <i>NRAS</i> (FOCUS4-D): a phase 2–3 randomised trial
- Adams, Richard; Brown, Ewan; Brown, Louise; Butler, Rachel; Falk, Stephen; Fisher, David; Kaplan, Richard; Quirke, Phil; Richman, Susan; Samuel, Leslie; Seligmann, Jenny; Seymour, Matt; Shiu, Kai Keen; Wasan, Harpreet; Wilson, Richard; Maughan, Tim; Cardiff University and Velindre Cancer Centre, Cardiff, UK; Edinburgh Cancer Centre NHS Lothian, Edinburgh, UK; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK; All Wales Genetics Laboratory University Hospital of Wales, Cardiff, UK; University Hospital Bristol NHS Foundation Trust, Bristol, UK; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK; Medical Research Council (MRC) Clinical Trials Unit at University College London (UCL), London, UK; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; Aberdeen Royal Infirmary, Aberdeen, UK; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK; University College London, London, UK; Imperial College London, London, UK; Centre for Cancer Research and; (The lancet. Gastroenterology & hepatology, v.3, 2018, pp.162-171)
-
14
- Investigating reduced-dimensional variability in aircraft-observed aerosol–cloud parameters
- Kayley M. Butler; Sam J. Silva; Armin Sorooshian; Richard H. Moore; Glenn S. Diskin; John B. Nowak; Luke Ziemba; Ewan Crosbie; Michael A. Shook; Joshua DiGangi; Edward Winstead; Claire Robinson; Yonghoon Choi; ; (Environmental Data Science, v.4, 2025, )
-
15
- Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
- Adams, Richard; Fisher, David; Graham, Janet; Seligmann, Jenny F.; Seymour, Matthew; Kaplan, Richard S.; Yates, Emma; Richman, Susan D; Quirke, Philip; Butler, Rachel; Brown, Ewan; Falk, Stephen; Collinson, Fiona Jane; Wilson, Richard H.; Brown, Louise C.; Maughan, Tim; Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom; ; University College London, London, United Kingdom; ; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; ; University of Leeds, Leeds, United Kingdom; ; Gastrointestinal Cancer Research Unit, Cookridge Hospital, Leeds, United Kingdom; ; Medical Research Council Clinical Trials Unit at UCL, London, United Kingdom; ; MRC Clinical Trials Unit at UCL, London, United Kingdom; ; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom; ; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom; ; SW Genomics Laboratory Hub, Bristol, United Kingdom; ; Western General Hospital, Edinburgh, United Kingdom; ; Bristol Oncology Centre, Bristol, United Kingdom; ; St James University Hospital, Felliscliffe Harrogate, United Kingdom; ; Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, Glasgow, United Kingdom; ; MRC Clinical; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.3504-3504)
-
16
- Clinical validation of a spectroscopic liquid biopsy for earlier detection of brain cancer
- Cameron, James M; Brennan, Paul M; Antoniou, Georgios; Butler, Holly J; Christie, Loren; Conn, Justin J A; Curran, Tom; Gray, Ewan; Hegarty, Mark G; Jenkinson, Michael D; Orringer, Daniel; Palmer, David S; Sala, Alexandra; Smith, Benjamin R; Baker, Matthew J; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh , UK; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Children’s Mercy Research Institute at the Children’s Mercy Hospital , Kansas City, Kansas , USA; Independent Health Economics Consultant , Edinburgh , UK; Dxcover Ltd. (formerly known as ClinSpec Diagnostics Ltd.) , Glasgow , UK; Institute of Translational Medicine, University of Liverpool & The; (Neuro-oncology advances, v.4, 2022, pp.vdac024)
-
17
- Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios
-
Gray, Ewan;
Butler, Holly J;
Board, Ruth;
Brennan, Paul M;
Chalmers, Anthony J;
Dawson, Timothy;
Goodden, John;
Hamilton, Willie;
Hegarty, Mark G;
James, Allan;
Jenkinson, Michael D;
Kernick, David;
Lekka, Elvira;
Livermore, Laurent J;
Mills, Samantha J;
O’Neill, Kevin;
Palmer, David S;
Vaqas, Babar;
Baker, Matthew J;
Health Improvement Scotland , Glasgow , UK;
Department of Pure and Applied Chemistry , University of Strathclyde Technology and Innovation Centre , Glasgow , UK;
Rosemere Cancer Centre , Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital , Preston , UK;
Department of Clinical Neurosciences , Western General Hospital , Edinburgh , UK;
Beatson West of Scotland Cancer Centre , Glasgow , UK;
Neurosurgery Department , Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital , Preston , UK;
Neurosurgery Department , Leeds General Infirmary , Leeds , UK;
Primary Care Diagnostics , University of Exeter Medical School, College House, University of Exeter , Exeter , UK;
Department of Pure and Applied Chemistry , University of Strathclyde Technology and Innovation Centre , Glasgow , UK
-
18
- The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
- Ricciardelli, Carmela; Bianco-Miotto, Tina; Jindal, Shalini; Butler, Lisa M.; Leung, Samuel; McNeil, Catriona M.; O'Toole, Sandra A.; Ebrahimie, Esmaeil; Millar, Ewan K.A.; Sakko, Andrew J.; Ruiz, Alexandra I.; Vowler, Sarah L.; Huntsman, David G.; Birrell, Stephen N.; Sutherland, Robert L.; Palmieri, Carlo; Hickey, Theresa E.; Tilley, Wayne D.; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of A; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.24, 2018, pp.2328-2341)
-
19
- Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial
- Adams, Richard A.; Fisher, David J.; Graham, Janet; Seligmann, Jenny F.; Seymour, Matthew; Kaplan, Richard; Yates, Emma; Parmar, Mahesh; Richman, Susan D.; Quirke, Philip; Butler, Rachel; Brown, Ewan; Collinson, Fiona; Falk, Stephen; Wasan, Harpreet; Shiu, Kai-Keen; Middleton, Gary; Samuel, Leslie; Wilson, Richard H.; Brown, Louise C.; Maughan, Timothy S.; Centre for Trials Research Cardiff University and Velindre NHS Trust, Cardiff, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Bristol Genetics Laboratory, Bristol, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Bristol Cancer Institute, Bristol, United Kingdom; Hammersmi; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.3693-3704)
-
20
- Inhibition of WEE1 Is Effective in <i>TP53</i> - and <i>RAS</i> -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
- Seligmann, Jenny F.; Fisher, David J.; Brown, Louise C.; Adams, Richard A.; Graham, Janet; Quirke, Philip; Richman, Susan D.; Butler, Rachel; Domingo, Enric; Blake, Andrew; Yates, Emma; Braun, Michael; Collinson, Fiona; Jones, Rob; Brown, Ewan; de Winton, Emma; Humphrey, Timothy C.; Parmar, Mahesh; Kaplan, Richard; Wilson, Richard H.; Seymour, Matthew; Maughan, Timothy S.; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; Centre for Trials Research University and Velindre NHS Trust, Cardiff, United Kingdom; Beatson Hospital, Glasgow, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; Bristol Genetics Laboratory, Bristol, United Kingdom; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom; MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom; MRC Clinical Trials Unit at UCL, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; School of Medicine, Cardiff University, Cardiff, United Kingdom; Western Gener; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.39, 2021, pp.3705-3715)
QUICK MENU
